Meeder Advisory Services Inc. Invests $996,000 in Biogen Inc. $BIIB

Meeder Advisory Services Inc. purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 4,608 shares of the biotechnology company’s stock, valued at approximately $996,000.

Several other institutional investors have also recently bought and sold shares of BIIB. Reflection Asset Management bought a new position in shares of Biogen in the fourth quarter valued at about $25,000. WPG Advisers LLC grew its holdings in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the last quarter. Bell Investment Advisors Inc bought a new stake in Biogen during the 2nd quarter worth about $27,000. First Horizon Corp acquired a new stake in Biogen in the 4th quarter valued at about $30,000. Finally, WFA of San Diego LLC acquired a new stake in Biogen in the 2nd quarter valued at about $32,000. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Up 4.2%

BIIB opened at $221.56 on Thursday. The firm has a 50 day simple moving average of $204.91 and a 200 day simple moving average of $194.08. Biogen Inc. has a fifty-two week low of $131.52 and a fifty-two week high of $222.15. The company has a market cap of $32.74 billion, a price-to-earnings ratio of 39.21, a price-to-earnings-growth ratio of 6.62 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period last year, the firm earned $5.47 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 12.39 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BIIB shares. Truist Financial upgraded shares of Biogen from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. The Goldman Sachs Group upped their price objective on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Morgan Stanley lifted their target price on Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Barclays boosted their target price on Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $227.07.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.